Profile data is unavailable for this security.
About the company
PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The Company's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.
- Revenue in AUD (TTM)26.17m
- Net income in AUD-50.30m
- Incorporated2001
- Employees23.00
- LocationPYC Therapeutics LtdHarry Perkins Institute, 6 Verdun StNEDLANDS 6009AustraliaAUS
- Phone+61 89316-9100
- Fax+61 89315-5475
- Websitehttps://pyctx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beijing Sun-Novo Pharma Research Co Ltd | 208.18m | 27.21m | 1.53bn | 1.36k | 54.87 | 6.42 | -- | 7.34 | 1.21 | 1.21 | 9.23 | 10.38 | 0.4745 | 35.48 | 1.28 | 653,956.40 | 6.04 | 11.39 | 10.49 | 18.82 | 48.60 | 53.31 | 12.72 | 19.66 | 1.78 | 9.97 | 0.3355 | 11.29 | 15.70 | 35.80 | -3.98 | 30.21 | 3.50 | -- |
| Abbisko Cayman Ltd | 126.75m | 30.72m | 1.56bn | 226.00 | 49.28 | 3.44 | 43.59 | 12.33 | 0.2608 | 0.2608 | 1.11 | 3.74 | 0.2634 | -- | 155.74 | 2,494,268.00 | 6.38 | -37.37 | 6.83 | -39.08 | 100.00 | -- | 24.24 | -625.86 | -- | -- | 0.0542 | -- | 2,544.24 | -- | 106.56 | -- | 16.58 | -- |
| Alphamab Oncology | 160.98m | 47.68m | 1.57bn | 484.00 | 34.14 | 4.10 | 25.22 | 9.76 | 0.2627 | 0.2627 | 0.8945 | 2.19 | 0.3492 | 0.8254 | 23.76 | 2,119,453.00 | 10.35 | -9.96 | 12.30 | -11.75 | 92.27 | -- | 29.62 | -103.28 | 4.75 | -- | 0.1285 | -- | 192.58 | -- | 178.99 | -- | -33.81 | -- |
| Shanghai Medicilon Inc | 220.75m | -47.43m | 1.83bn | 2.27k | -- | 4.33 | -- | 8.27 | -1.75 | -1.75 | 8.04 | 15.36 | 0.3759 | 8.56 | 1.68 | 459,338.00 | -8.08 | 3.66 | -9.99 | 4.63 | 16.27 | 31.15 | -21.49 | 6.67 | 2.19 | -- | 0.1508 | 40.97 | -24.01 | 18.22 | -896.21 | -- | 2.54 | -- |
| Peptidream Inc | 165.96m | -53.90m | 1.83bn | 621.00 | -- | 3.73 | -- | 11.01 | -44.98 | -44.98 | 138.55 | 407.05 | 0.2097 | 3.63 | 3.73 | 28,872,100.00 | -6.81 | 13.49 | -8.01 | 15.79 | 37.93 | 70.05 | -32.48 | 26.45 | 4.35 | -26.17 | 0.2517 | 0.00 | 62.57 | -- | 394.59 | -- | -- | -- |
| PYC Therapeutics Ltd | 26.17m | -50.30m | 1.95bn | 23.00 | -- | 5.36 | -- | 74.56 | -0.0987 | -0.0987 | 0.0511 | 0.2824 | 0.1907 | -- | 66.76 | -- | -37.17 | -42.88 | -40.47 | -47.98 | -- | -- | -194.92 | -172.76 | -- | -39.28 | 0.006 | -- | 14.51 | 58.66 | -33.34 | -- | 55.85 | -- |
| Pell Bio Med Technology Co Ltd | 1.35m | -16.81m | 1.98bn | -- | -- | 41.98 | -- | 1,467.90 | -6.31 | -6.31 | 0.5068 | 16.15 | 0.0185 | 6.36 | 5.95 | -- | -23.99 | -- | -31.28 | -- | -31.12 | -- | -1,297.25 | -- | 3.47 | -- | 0.1652 | -- | 8.86 | -- | 2.34 | -- | -- | -- |
| Bio-Thera Solutions Ltd | 172.94m | -75.46m | 2.01bn | 1.17k | -- | 20.27 | -- | 11.61 | -0.8908 | -0.8908 | 2.04 | 1.17 | 0.3702 | 0.7722 | 5.96 | -- | -16.15 | -16.38 | -33.76 | -22.22 | 74.99 | 77.05 | -43.63 | -62.11 | 0.4617 | -34.12 | 0.573 | -- | 5.44 | 302.90 | -29.34 | -- | 11.14 | -- |
| Rubicon Research Ltd | 249.45m | 32.18m | 2.02bn | 1.14k | 60.03 | -- | 52.72 | 8.09 | 13.07 | 13.07 | 102.06 | -- | -- | -- | -- | 14,424,080.00 | -- | -- | -- | -- | 68.82 | -- | 12.90 | -- | -- | 12.92 | -- | -- | 50.40 | -- | 47.63 | -- | -- | -- |
| GenFleet Therapeutics (Shanghai) Inc | 39.62m | -189.85m | 2.02bn | 94.00 | -- | -- | -- | 51.08 | -3.04 | -3.04 | 0.6344 | -8.66 | -- | -- | -- | -- | -- | -- | -- | -- | 80.86 | -- | -479.17 | -- | 0.1655 | -23.43 | -- | -- | 42.00 | -- | -33.31 | -- | -- | -- |
| Onesource Specialty Pharma Ltd | 221.54m | 3.25m | 2.12bn | 1.41k | 651.79 | -- | 45.81 | 9.57 | 1.82 | 1.76 | 129.84 | -- | -- | -- | -- | 10,051,880.00 | -- | -- | -- | -- | 70.99 | -- | 1.46 | -- | -- | 0.8886 | -- | -- | 740.43 | -- | 95.27 | -- | -- | -- |
| Suzhou Ribo Life Science Co Ltd | 36.89m | -45.21m | 2.16bn | 404.00 | -- | -- | -- | 58.56 | -1.55 | -1.55 | 1.26 | -0.4093 | -- | -- | -- | -- | -- | -- | -- | -- | 90.90 | -- | -131.95 | -- | 0.9173 | -14.93 | 0.8949 | -- | 324,052.30 | -- | 36.93 | -- | -- | -- |
| Nanjing Leads Biolabs Co Ltd | 0.00 | -58.83m | 2.21bn | 192.00 | -- | 97.39 | -- | -- | -2.01 | -2.01 | 0.00 | 0.6299 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.01 | -- | 0.7407 | -- | -100.00 | -- | 16.85 | -- | -- | -- |
Data as of Feb 16 2026. Currency figures normalised to PYC Therapeutics Ltd's reporting currency: Australian Dollar AUD
23.30%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 11 Feb 2026 | 83.85m | 14.38% |
| Firetrail Investments Pty Ltd.as of 05 Nov 2025 | 29.49m | 5.06% |
| Wilson Asset Management (International) Pty Ltd.as of 30 Jun 2025 | 10.31m | 1.77% |
| Samarang LLPas of 30 Jun 2025 | 8.50m | 1.46% |
| FIL Investment Management (Hong Kong) Ltd.as of 31 Dec 2025 | 2.40m | 0.41% |
| FIL Pensions Managementas of 30 Jun 2025 | 891.77k | 0.15% |
| Russell Investment Management Ltd.as of 30 Sep 2025 | 458.35k | 0.08% |
| Global X Management (AUS) Ltd.as of 05 Feb 2026 | 1.52k | 0.00% |
More ▼
Data from 30 Jun 2025 - 11 Feb 2026Source: FactSet Research Systems Inc.
